Rhumbline Advisers Purchases 1,923 Shares of Kura Oncology, Inc. (NASDAQ:KURA)

Rhumbline Advisers grew its position in Kura Oncology, Inc. (NASDAQ:KURA) by 2.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 99,991 shares of the company’s stock after buying an additional 1,923 shares during the quarter. Rhumbline Advisers owned 0.13% of Kura Oncology worth $871,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in KURA. Point72 DIFC Ltd acquired a new position in Kura Oncology during the third quarter valued at approximately $146,000. Erste Asset Management GmbH bought a new position in shares of Kura Oncology in the 3rd quarter valued at $215,000. Bellevue Group AG raised its holdings in shares of Kura Oncology by 36.0% during the 3rd quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock worth $266,000 after buying an additional 3,600 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Kura Oncology during the 3rd quarter worth $268,000. Finally, Intech Investment Management LLC acquired a new stake in Kura Oncology in the third quarter valued at about $298,000.

Analysts Set New Price Targets

Several research analysts have commented on KURA shares. JMP Securities reissued a “market outperform” rating and set a $28.00 target price on shares of Kura Oncology in a research note on Thursday, February 6th. Jefferies Financial Group lowered their price objective on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday, November 21st. TD Cowen reissued a “buy” rating on shares of Kura Oncology in a research note on Thursday, November 21st. Scotiabank dropped their price target on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 8th. Finally, Bank of America cut their price objective on Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a report on Friday, November 22nd. Three equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $25.50.

Insider Transactions at Kura Oncology

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. This represents a 5.31 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the sale, the insider now owns 88,253 shares of the company’s stock, valued at $694,551.11. This represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,729 shares of company stock worth $92,307. Company insiders own 5.50% of the company’s stock.

Kura Oncology Stock Up 4.5 %

Shares of KURA opened at $7.70 on Friday. The company has a market capitalization of $598.78 million, a PE ratio of -3.26 and a beta of 0.85. The stock’s 50-day moving average price is $8.04 and its two-hundred day moving average price is $13.51. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a 12 month low of $6.98 and a 12 month high of $24.17.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.43. The company had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million. On average, analysts anticipate that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.